托珠单抗联合或不联合甲氨蝶呤维持治疗类风湿关节炎的 retention:ACTRA-RI 队列研究
510 例高/中度 CDAI 患者中 328 例(64.3%)为 CDAI50 应答者,应答者 MTX 使用率 53.0%。维持期平均随访 30.7 个月,43.9% 的 CDAI50 应答者停用 TCZ,最常见原因为疗效丧失。Kaplan-Meier 估计 TCZ 留存时间单药组 48.3 个月(95% CI 42.0, 54.5)、联合组 50.0 个月(95% CI 45.9, 54.0),Gray 检验显示 MTX 使用对疗效丧失或不良事件的累积发生率无显著影响。
要点
- 第一年达 CDAI50 的 RA 患者中,MTX 联合与否不影响 TCZ 维持期留存。
- 维持期 43.9% 的 CDAI50 应答者停用 TCZ,疗效丧失最常见。
- 维持治疗开始时 CDAI>10 和年龄分别是疗效丧失和不良事件停药的预测因素。
核心结论
- TCZ 单药与联合 MTX 在 CDAI50 应答者维持治疗中的留存无显著差异。
研究设计与样本
- 510 例高或中度 CDAI 患者中 328 例(64.3%)为第一年 CDAI50 应答者,纳入维持期分析。
主要发现
- CDAI50 应答者 MTX 使用率 53.0%,非应答者 54.4%。
- 维持期平均随访 30.7 个月,43.9% 的 CDAI50 应答者停用 TCZ,最常见原因为疗效丧失。
- Kaplan-Meier 估计 TCZ 留存时间单药组 48.3 个月(95% CI 42.0, 54.5),联合组 50.0 个月(95% CI 45.9, 54.0)。
- Gray 检验显示 MTX 使用对疗效丧失或不良事件的累积发生率无显著影响。
- Fine-Gray 竞争风险回归中,维持治疗开始时 CDAI>10 预测疗效丧失停药(HR 2.58, 95% CI 1.41, 4.72),年龄预测不良事件停药(HR 1.04, 95% CI 1.01, 1.08)。
临床怎么用
- 对于第一年达到 CDAI50 的 RA 患者,维持期可考虑 TCZ 单药治疗而不强制联合 MTX。
- 维持治疗开始时 CDAI>10 提示疗效丧失停药风险较高,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare retention of tocilizumab (TCZ) as monotherapy vs combination therapy with MTX in RA patients achieving clinical improvements during the first year. METHODS: We performed a multicentre cohort study using a real-life registry containing RA patients who had begun TCZ with or without MTX between April 2008 and November 2016. Among patients with ≥50% improvement of clinical disease activity index (CDAI) during the first year (CDAI50 responders), we evaluated whether MTX use may have affected TCZ discontinuation during the second and subsequent years (maintenance therapy). RESULTS: Among 510 patients with high or moderate CDAI, 328 (64.3%) were CDAI50 responders. The rate of MTX use was 53.0% among responders and 54.4% among non-responders. During maintenance therapy (mean follow-up 30.7 months), 43.9% of CDAI50 responders discontinued TCZ. The most common cause was efficacy loss followed by adverse events. Kaplan-Meier estimates for TCZ retention were 48.3 months (95% CI 42.0, 54.5) for monotherapy and 50.0 months (95% CI 45.9, 54.0) for combination therapy. According to Gray's test, there was no significant impact of MTX use on cumulative incidence of efficacy loss or adverse events. In the Fine-Gray competing risk regression model, CDAI >10 at the start of maintenance therapy and age were predictive factors for TCZ discontinuation due to efficacy loss (hazard ratio 2.58, 95% CI 1.41, 4.72) and adverse events (hazard ratio 1.04, 95% CI 1.01, 1.08), respectively. CONCLUSION: There was no significant difference in TCZ retention between monotherapy and combination therapy with MTX.
引用
- Mori S, Yoshitama T, Abe Y, et al. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study. Rheumatology (Oxford). 2019. PMID: 30793749. doi:10.1093/rheumatology/kez021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。